TGFB1 and leukemia: Thus, by treating mice with leukemia-derived EVs carrying lower TGF-β1 levels prolonged animal survival, suggesting that such EVs were more effective in both protective and therapeutic antitumor tests than non-modified EVs carrying a higher load of TGF-β1 (Huang et al., 2017).